Drug Discovery World

AUGUST 16, 2024

The chosen news highlights this week all feature advances in drug development in oncology indications and reflect the breadth of therapeutic approaches to cancer treatment. First claudin 18.2 monoclonal antibody.

Licensing 147

Licensing Licensing Drugs Clinical Trials 147

Drug Discovery World

APRIL 17, 2024

Biotechnology company Arvinas has entered into an exclusive strategic license agreement with Novartis for ARV-766, Arvinas’ second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer. Arvinas will receive an upfront payment in the aggregate amount of $150 million.

Licensing 130

Licensing Licensing Clinical Development Treatment 130

Drug Discovery World

JANUARY 2, 2024

Cancer Research Horizon’s Innovation Summit 2023 took place on 21 November 2023 at the Royal Society of Medicine, and included talks from researchers translating their research, as well as networking with members of the entrepreneurial ecosystem. DDW’s Megan Thomas spoke to a range of attendees.

Research 147

Research Vaccine Science Trials 147

Drug Discovery World

AUGUST 23, 2022

The European Medicines Agency (EMA) has granted a Marketing Authorisation Application (MAA) for a combination treatment targeting adults with acute myeloid leukaemia (AML) who are not candidates for standard induction chemotherapy. . Poster presented at EHA Annual Meeting, Vienna, Austria June 9 – 12, 2022. Abstract P573.

Treatment 130

Treatment Pharmacokinetics Clinical Trials DNA 130

Drug Discovery World

DECEMBER 7, 2023

A potential schizophrenia treatment, discovered at Vanderbilt University in Tennessee in the US, has been cleared by the US Food and Drug Administration for use in Phase I clinical trials. It was discovered in the labs of Craig Lindsley, Director of the Warren Center for Neuroscience Drug Discovery (WCNDD) and Director Emeritus Jeffrey Conn.

Trials 299

Trials Drugs Clinical Trials Licensing 299

Drug Discovery World

FEBRUARY 9, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to AstraZeneca for Imfinzi (durvalumab) in combination with gemcitabine and cisplatin in Great Britain for use as a first-line treatment of adults with locally advanced, unresectable or metastatic biliary tract cancer (BTC). versus 11.5%).

Treatment 130

Treatment Clinical Research International FDA 130

Drug Discovery World

JULY 2, 2024

City of Hope, US, researchers are now in discussions with the global SWOG Cancer Research Network to design a Phase II/III trial to assess the novel use of CBM588 and microbiome modulation in people with advanced cancer. Scientists from Osel and Miyarisan Pharmaceutical, the manufacturer of CBM588, collaborated on the study.

Trials 147

Trials Treatment Clinical Trials Licensing 147

Drug Discovery World

AUGUST 8, 2023

Astex Pharmaceuticals and MSD (Merck & Co) have announced an exclusive worldwide research collaboration to identify small molecule candidates with activity towards a tumour suppressor protein for the treatment of cancer.

Small Molecule 246

Small Molecule Drugs Licensing Licensing 246

Drug Discovery World

JUNE 1, 2023

According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1. A market research report published in late June 2018 by HTF market Intelligence Consulting suggested that the ADC market in China would grow exponentially by 2023 4.

Marketing 245

Marketing FDA Approval Licensing Licensing 245

Drug Discovery World

MARCH 12, 2024

Elicera Therapeutics will make parts of its technology iTANK available to a medical oncologist and researcher at the undisclosed US cancer centre, whose investigation focuses on the development of novel immunotherapies. The iTANK technology platform has been developed for arming and enhancing CAR T-cells for the treatment of solid tumours.

Therapies 130

Therapies Immune Response Licensing Licensing 130

The Pharma Data

MARCH 9, 2022

Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets.

Licensing 52

Licensing Licensing Therapies Disease 52

Drug Discovery World

JULY 26, 2023

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The drug, MOv18 IgE, was developed by researchers at King’s College London.

Clinical Trials 130

Clinical Trials Immune Response Drugs Trials 130

Drug Discovery World

JULY 28, 2023

The top stories: Partnership could enhance antibody discovery for cancer research Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries. New eBook: Breakthroughs accelerating therapeutic antibodies The latest eBook by DDW is out now.

Clinical Trials 130

Clinical Trials Licensing Licensing Drugs 130

Drug Discovery World

AUGUST 21, 2024

Adcendo and Multitude Therapeutics have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

Drug Target Review

SEPTEMBER 5, 2024

However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company. I am a pharmacist by training and continued with a PhD in Clinical Pharmacology.

Pharma Companies 111

Pharma Companies Licensing Licensing Disease 111

Drug Discovery World

JULY 18, 2024

The UK has the potential to become the global leader in pharmaceutical cannabinoid R&D, according to a new report published by the Cannabinoid Research and Development Group (CRDG). The British Pharmacopoeia and associated regulatory agencies should review monographs for various CBPMs and synthetic cannabinoids.

Science 130

Science Government Pharmaceuticals Regulations 130

Drug Discovery World

FEBRUARY 23, 2024

FDA approves first T cell therapy in solid tumours The US Food and Drug Administration has approved Amtagvi (lifileucel), the first cellular therapy indicated for the treatment of metastatic, unresectable melanoma. £7M The post This week in drug discovery (19-23 February) appeared first on Drug Discovery World (DDW).

FDA Approval 130

FDA Approval Therapies Licensing Licensing 130

Drug Discovery World

AUGUST 1, 2023

Partnerships Earlier this year cell-engineering company MaxCyte signed a strategic platform license (SPL) with biotechnology company Catamaran Bio. In return MaxCyte will receive platform licensing fees and program-related revenue.

Drugs 130

Drugs Licensing Licensing Engineering 130

Drug Discovery World

MARCH 25, 2024

Allogene Therapeutics and Arbor Biotechnologies Biotechnology companies Allogene Therapeutics and Arbor Biotechnologies entered a non-exclusive, global gene editing licensing agreement for use of Arbor’s proprietary CRISPR gene-editing technology in Allogene’s AlloCAR T platform for the treatment of autoimmune disease (AID).

Drugs 130

Drugs Licensing Licensing Laboratories 130

LifeSciVC

JULY 17, 2024

Reaching the end goal of delivering transformational new treatment options for patients can take a decade or more even when companies execute successfully and are well capitalized. Fortunately, AbbVie felt the same way, which is why we initiated discussions to in-license AbbVie’s most promising CF pipeline programs.

Clinical Research 45

Clinical Research Disease Research Clinical Trials 45

Drug Discovery World

OCTOBER 21, 2022

Under an exclusive agreement, Jazz Pharmaceuticals will acquire development and commercialisation rights to Zymeworks’ zanidatamab across all indications and all territories except for those Asia/Pacific territories previously licensed by Zymeworks. billion, plus royalties on net sales. billion, plus royalties on net sales.

Licensing 130

Licensing Licensing Treatment Pharmaceuticals 130

Drug Discovery World

AUGUST 14, 2023

Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. We hope that this EP4-targeting approach will deliver a promising route to improving treatment options for patients with a broad range of cancers.”

Trials 130

Trials Small Molecule Pharmacokinetics Clinical Trials 130

Drug Discovery World

MARCH 6, 2024

This second ODD allows research and development of a therapy for another form of the disease, Isolated Hypomyelination. The technology has been proven in the treatment of other dystrophies, including Duchenne muscular dystrophy, and is quick and cost-effective to develop.

Disease 130

Disease FDA Therapies Drugs 130

The Pharma Data

OCTOBER 27, 2021

NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders. About MODAG.

Licensing 52

Licensing Licensing Disease Small Molecule 52

The Pharma Data

MARCH 31, 2023

AstraZeneca has completed an exclusive global license agreement with KYM Biosciences Inc. CMG901 is currently being evaluated in a Phase I trial for the treatment of Claudin 18.2-positive CMG901 is being developed for the treatment of solid tumours that express the cell surface protein Claudin 18.2, including gastric cancers.

Licensing 40

Licensing Licensing Small Molecule Drugs 40

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Licensing 52

Licensing Licensing Therapies Science 52

Drug Discovery World

FEBRUARY 22, 2024

Astellas-owned Xyphos Biosciences and Kelonia Therapeutics have entered into a research collaboration and license agreement to develop novel immuno-oncology therapeutics. Xyphos will be responsible for the development and commercialisation of products created from the collaborative research.

Therapies 130

Therapies Licensing Licensing Research 130

Drug Discovery World

OCTOBER 6, 2023

Researchers uncover molecular pathways underlying depression Scientists have discovered the link between gene expression, DNA methylation, and brain structural changes in depression, revealing new potential therapeutic targets.

Drugs 130

Drugs DNA Licensing Licensing 130

Drug Discovery World

AUGUST 9, 2023

The company’s collaboration partner, Cancer Research UK’s Centre for Drug Development, has sponsored and will conduct the Phase I/II clinical trial. ALETA-001 is working to address this treatment gap for people with blood cancers by advancing a potentially life-saving CAR T cell therapy into the clinic.

Clinical Trials 130

Clinical Trials Trials Therapies Licensing 130

Drug Discovery World

SEPTEMBER 8, 2023

This week we have seen the vital importance of collaboration to the successful development and discovery of novel therapeutics, exemplified by the new deal agreed by the UK and EU to admit the UK back into Horizon Europe, the largest collaborative research programme in the world.

Drugs 130

Drugs Licensing Licensing Government 130

Drug Discovery World

NOVEMBER 25, 2022

Gene therapies have made the headlines over the last few days, with treatments for rare AADC deficiency, lung cancer and haemophilia B given the go ahead from regulators. Scientists have found a new drug treatment that can slow the progression of neurodegenerative disease in mice. The top stories: .

FDA Approval 130

FDA Approval FDA Drugs Therapies 130

Drug Discovery World

MAY 31, 2023

The MAA is for the treatment of early Alzheimer’s disease (AD) (mild cognitive impairment due to AD and mild AD dementia) with confirmed amyloid pathology in the brain. The investigational therapy has been designated by the MHRA for the Innovative Licensing and Access Pathway (ILAP).

Licensing 130

Licensing Licensing Treatment Production 130

Drug Discovery World

JULY 22, 2024

Opportunities and potential According to Loiacono, the impact of CAR-T therapies on the treatment of select cancers has been powerful and these therapies have become known for their curative potential and durability. Loiacono reflects that the growth in the sector, although substantial, requires concerted efforts across domains.

Therapies 130

Therapies Engineering Treatment Pharma Companies 130

Conversations in Drug Development Trends

NOVEMBER 27, 2023

Casgevy, the commercial product formerly known as exa-cel, is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory, with the modified cells then infused back into the patient after conditioning treatment to prepare the bone marrow. In June 2023, the U.S.

Treatment 75

Treatment FDA Clinical Trials Therapies 75

Drug Discovery World

OCTOBER 4, 2023

The US Food and Drug Administration (FDA) has accepted Rocket Pharmaceuticals’ Biologics License Application (BLA) and granted Priority Review for RP-L201 (marnetegragene autotemcel). All of these children have been in good health with no significant LAD-I-related infections or inflammatory skin lesions since treatment.

FDA 130

FDA Therapies Pharmaceuticals Licensing 130

Drug Discovery World

JANUARY 15, 2024

Evotec and the Crohn’s & Colitis Foundation Evotec has joined forces with the Crohn’s & Colitis Foundation, a non-profit organisation focused on research and patient support for inflammatory bowel disease (IBD). of Perspective’s shares for up to $33 million.

Targeted Protein Degradation 147

Targeted Protein Degradation Drugs Small Molecule Licensing 147

Drug Discovery World

SEPTEMBER 27, 2023

The therapy is now recommended within an NHS setting for the treatment of adults with newly diagnosed MM where an autologous stem cell transplant (ASCT) is unsuitable. Seven years of trial data DLd is licensed and has been available for use in Europe since 2019.

Regulations 130

Regulations Licensing Licensing Therapies 130